{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:51:22Z","timestamp":1781117482035,"version":"3.54.1"},"reference-count":32,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,8,11]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec><jats:title>Question addressed by the study<\/jats:title><jats:p>Do three coronavirus disease 2019 (COVID-19) vaccine doses induce a serological response in lung transplant recipients?<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively included 1071 adults (551 (52%) males) at nine transplant centres in France. Each had received three COVID-19 vaccine doses in 2021, after lung transplantation. An anti-spike protein IgG response, defined as a titre &gt;264\u2005BAU\u00b7mL<jats:sup>\u22121<\/jats:sup>after the third dose (median (interquartile range (IQR)) 3.0 (1.7\u20134.1)\u2005months), was the primary outcome and adverse events were the secondary outcomes. Median (IQR) age at the first vaccine dose was 54 (40\u201363)\u2005years and median (IQR) time from transplantation to the first dose was 64 (30\u2013110)\u2005months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median (IQR) follow-up after the first dose was 8.3 (6.7\u20139.3)\u2005months. A vaccine response developed in 173 (16%) patients. Factors independently associated with a response were younger age at vaccination, longer time from transplantation to vaccination and absence of corticosteroid or mycophenolate therapy. After vaccination, 51 (5%) patients (47 non-responders (47\/898 (5%)) and four (4\/173 (2%)) responders) experienced COVID-19, at a median (IQR) of 6.6 (5.1\u20137.3)\u2005months after the third dose. No responders had severe COVID-19 compared with 15 non-responders, including six who died of the disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Few lung transplant recipients achieved a serological response to three COVID-19 vaccine doses, indicating a need for other protective measures. Older age and use of mycophenolate or corticosteroids were associated with absence of a response. The low incidence of COVID-19 might reflect vaccine protection<jats:italic>via<\/jats:italic>cellular immunity and\/or good adherence to shielding measures.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.00502-2022","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T14:35:26Z","timestamp":1666276526000},"page":"2200502","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study"],"prefix":"10.1183","volume":"61","author":[{"given":"Ga\u00eblle","family":"Dauriat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5235-0868","authenticated-orcid":false,"given":"Liem Binh","family":"Luong Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-9486","authenticated-orcid":false,"given":"Benjamin","family":"Renaud Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Penhouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Coiffard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Salpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Demant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Saint Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-608X","authenticated-orcid":false,"given":"Nicolas","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-3527","authenticated-orcid":false,"given":"Jonathan","family":"Messika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Reynaud Gaubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Danner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-9391","authenticated-orcid":false,"given":"Floriane","family":"Gallais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Le Pavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"2024102103042726000_61.1.2200502.1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16424"},{"key":"2024102103042726000_61.1.2200502.2","doi-asserted-by":"crossref","first-page":"e4090","DOI":"10.1093\/cid\/ciaa1097","article-title":"Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study","volume":"73","author":"Kates","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024102103042726000_61.1.2200502.3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/TP.0000000000003508","article-title":"COVID-19 in lung transplant recipients","volume":"105","author":"Messika","year":"2021","journal-title":"Transplantation"},{"key":"2024102103042726000_61.1.2200502.4","unstructured":"BioNTech SE . A phase 1\/2\/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-COV-2 RNA vaccine candidates against COVID-19 in healthy individuals. 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04368728 Date last accessed: 17 January 2022."},{"key":"2024102103042726000_61.1.2200502.5","unstructured":"ModernaTX, Inc. A phase 3, randomized, stratified, observer-blind, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine in adults aged 18\u2005years and older. 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04470427 Date last accessed: 17 January 2022."},{"key":"2024102103042726000_61.1.2200502.6","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/TP.0000000000003637","article-title":"Early development and durability of SARS-CoV-2 antibodies among solid organ transplant recipients: a pilot study","volume":"105","author":"Boyarsky","year":"2021","journal-title":"Transplantation"},{"key":"2024102103042726000_61.1.2200502.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.08.017"},{"key":"2024102103042726000_61.1.2200502.8","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.2021.12339","article-title":"Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses","volume":"326","author":"Benotmane","year":"2021","journal-title":"JAMA"},{"key":"2024102103042726000_61.1.2200502.9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/ajt.16775","article-title":"Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients","volume":"22","author":"Del Bello","year":"2022","journal-title":"Am J Transplant"},{"key":"2024102103042726000_61.1.2200502.10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2111462"},{"key":"2024102103042726000_61.1.2200502.11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2108861"},{"key":"2024102103042726000_61.1.2200502.12","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1097\/TP.0000000000003903","article-title":"Cellular and humoral immune responses after 3 doses of BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant","volume":"105","author":"Stumpf","year":"2021","journal-title":"Transplantation"},{"key":"2024102103042726000_61.1.2200502.13","doi-asserted-by":"publisher","DOI":"10.7326\/L21-0282"},{"key":"2024102103042726000_61.1.2200502.14","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2021.7489"},{"key":"2024102103042726000_61.1.2200502.15","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.healun.2021.07.026","article-title":"SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients","volume":"40","author":"Hallett","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2024102103042726000_61.1.2200502.16","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2213-2600(21)00184-3","article-title":"Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine","volume":"9","author":"Shostak","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103042726000_61.1.2200502.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4385"},{"key":"2024102103042726000_61.1.2200502.18","unstructured":"Conseil d'Orientation de la Strat\u00e9gie Vaccinale . Recommandations pour la protection des personnes s\u00e9v\u00e8rement immunod\u00e9prim\u00e9es contre le Covid-19 (Vaccination et prophylaxie primaire) \u2013 19 Novembre 2021. [Recommendations for the protection of severely immunocompromised people against Covid-19 (Vaccination and primary prophylaxis) \u2013 19 November 2021.] 2021. https:\/\/solidarites-sante.gouv.fr\/IMG\/pdf\/cosv_-_recommandations_pour_la_protection_des_personnes_severement_immunodeprimees_-_19_novembre_2021.pdf Date last accessed: 2 February 2022."},{"key":"2024102103042726000_61.1.2200502.19","unstructured":"Conseil d'Orientation de la Strat\u00e9gie Vaccinale . Avis du 13 avril 2021 \u2013 La s\u00e9rologie Covid-19 post-vaccination en population g\u00e9n\u00e9rale est-elle justifi\u00e9e? \u2013 Mise \u00e0 jour du 26 novembre 2021. [Opinion of 13 April 2021 \u2013 Is post-vaccination Covid-19 serology in the general population justified? \u2013 Update of 26 November 2021.] 2021. https:\/\/solidarites-sante.gouv.fr\/IMG\/pdf\/cosv_-_mise_a_jour_du_26_novembre_2021_de_l_avis_du_cosv_13_avril_2021_-_serologies_en_population_generale.pdf Date last accessed: 10 June 2022."},{"key":"2024102103042726000_61.1.2200502.20","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"2024102103042726000_61.1.2200502.21","unstructured":"World Health Organization. Living guidance for clinical management of COVID-19. Living guidance: 23 November 2021. 2021. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/349321\/WHO-2019-nCoV-clinical-2021.2-eng.pdf Date last accessed: 26 May 2022."},{"key":"2024102103042726000_61.1.2200502.22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"2024102103042726000_61.1.2200502.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07849-2"},{"key":"2024102103042726000_61.1.2200502.24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"2024102103042726000_61.1.2200502.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108095"},{"key":"2024102103042726000_61.1.2200502.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2024102103042726000_61.1.2200502.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2024102103042726000_61.1.2200502.28","unstructured":"Sant\u00e9 Publique France . Coronavirus: chiffres cl\u00e9s et \u00e9volution de la COVID-19 en France et dans le Monde. [Coronavirus: key figures and evolution of COVID-19 in France and around the world.] 2022. www.santepubliquefrance.fr\/dossiers\/coronavirus-covid-19\/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde Date last accessed: 14 February 2022."},{"key":"2024102103042726000_61.1.2200502.29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","article-title":"Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine","volume":"597","author":"Oberhardt","year":"2021","journal-title":"Nature"},{"key":"2024102103042726000_61.1.2200502.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01122-w"},{"key":"2024102103042726000_61.1.2200502.31","doi-asserted-by":"crossref","first-page":"e2212073","DOI":"10.1001\/jamanetworkopen.2022.12073","article-title":"Neutralizing antibodies against the SARS-CoV-2 omicron variant (BA.1) 1 to 18\u2005weeks after the second and third doses of the BNT162b2 mRNA vaccine","volume":"5","author":"Lassauni\u00e8re","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024102103042726000_61.1.2200502.32","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00409-1"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00502-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:09:42Z","timestamp":1740380982000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00502-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,19]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1183\/13993003.00502-2022"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00502-2022","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}